Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis

Rheumatology

Volumn 41, Issue 4, 2002, Pages 430-439

  Barrera, P ^a   Van Der Maas, A ^a   Van Ede, A E ^a   Kiemeney, B A L M ^a   Laan, R F J M ^a   Van De Putte, L B A ^a   Van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arthritis; Methotrexate therapeutic use; Rheumatoid drug therapy; Tumour necrosis factor antagonists and inhibitors

Indexed keywords

ANTIRHEUMATIC AGENT; FOLIC ACID; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOTREXATE; PATIENT DROPOUTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036107631     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
2. Tumor necrosis factor inhibitors for rheumatoid arthritis
3. TNF alpha is an effective therapeutic target for rheumatoid arthritis
4. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
5. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
6. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
7. One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis
8. Long term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis
9. Update on D2E7: A fully human anti-tumor necrosis factor α monoclonal antibody
10. Long-term use of the fully human anti-TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis
11. Combination therapy with biologic agents in rheumatoid arthritis: Perils and promise
12. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
13. Anti-TNF alpha monoclonal antibody, Infliximab (chimeric antitumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
14. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
15. Generation of fully human anti-TNF antibody D2E7
16. Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis
17. Infliximab and methotrexate in the treatment of rheumatoid arthritis
18. Effect of folic or folinic acid supplementation on toxicity and efficacy of methotrexate in rheumatoid arthritis. A double-blind, randomized, placebo-controlled, multicenter 48-week study
19. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity
20. The use of folates concomitantly with low-dose pulse methotrexate
21. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial
22. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
23. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
24. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health League Against Rheumatism criteria
25. Adverse events in methotrexate-treated rheumatoid arthritis patients
26. The relative toxicity of alternative therapies for rheumatoid arthritis: Implications for the therapeutic progression
27. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine
28. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial
29. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial
30. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update
31. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years
32. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
33. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial
34. Long-term prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy
35. Methotrexate, the relationship between dose and clinical effect
36. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
37. Combination of second-line antirheumatic drugs
38. Combination therapy in rheumatoid arthritis: Updated systematic review
39. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
40. Subgroup analyses show consistent clinical benefit in the ATTRACT trial: Anti-TNFa monoclonal antibody, Infliximab, in RA patients on methotrexate
41. Factors predicting response to treatment in rheumatoid arthritis
42. Long-term second line treatment: A prospective drug-survival study